Last Updated: November 16, 2026

Investigational Drug Information for HSG4112

« Back to Dashboard


What is the development status for investigational drug HSG4112?

HSG4112 is an investigational drug.

There have been 5 clinical trials for HSG4112. The most recent clinical trial was a Phase 1 trial, which was initiated on January 31st 2022.

The most common disease conditions in clinical trials are Overweight and [disabled in preview]. The leading clinical trial sponsors are Glaceum, Seoul National University Hospital, and Kyungpook National University Hospital.

There are four US patents protecting this investigational drug.

Recent Clinical Trials for HSG4112
TitleSponsorPhase
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High DosesSeoul National University HospitalPhase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High DosesGlaceumPhase 1
A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese PatientsGangnam Severance HospitalPhase 2

See all HSG4112 clinical trials

Clinical Trial Summary for HSG4112

Top disease conditions for HSG4112
Top clinical trial sponsors for HSG4112

See all HSG4112 clinical trials

US Patents for HSG4112

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
HSG4112 ⤷  Start Trial Method for synthesizing 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2.3-f]chromene derivative and optical isomer of thereof Glaceum Inc ⤷  Start Trial
HSG4112 ⤷  Start Trial 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative and method for synthesizing optical isomer thereof Glaceum Inc ⤷  Start Trial
HSG4112 ⤷  Start Trial Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same Glaceum Inc ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.